Elutia:1st patient implanted with biologic envelope EluPro for pacemakers

Elutia announced a landmark achievement with the first-ever patient implant of EluPro the world’s first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration . The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clinical Cardiac Electrophysiology Fellowship at East Carolina University Health Medical Center in Greenville, North Carolina…The launch of EluPro presents a major opportunity in the $600 million U.S. implantable electronic device protection market, which has previously been served by a single competitor with a synthetic envelope. In addition to establishing a strong presence in the broader $8 billion cardiac rhythm management market, Elutia is also targeting adjacent neurostimulation and modulation sectors, which represent another $8 billion opportunity.